In vitro susceptibility of thirty borrelia strains from various sources against eight antimicrobial chemotherapeutics

Infection

Volumn 24, Issue 1, 1996, Pages 60-63

  Baradaran Dilmaghani, R ^a   Stanek, G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CEFOTAXIME; CEFTRIAXONE; COTRIMOXAZOLE; DOXYCYCLINE; PENICILLIN G SODIUM; ROXITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; BORRELIA; BORRELIA BURGDORFERI; CONFERENCE PAPER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

AMOXICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BORRELIA; BORRELIA BURGDORFERI GROUP; CEFOTAXIME; CEFTRIAXONE; DOXYCYCLINE; HUMANS; LYME DISEASE; MICROBIAL SENSITIVITY TESTS; PENICILLIN G; ROXITHROMYCIN; TICKS; TIME FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0030066682     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01780660     Document Type: Conference Paper

References (11)

1. Steere, A. C., Hutchinson, G. J., Rahn, D. W., Sigal, L. H., Craft, J. E., De Sanna, E. T.: Treatment of the early manifestations of Lyme disease. Ann. Intern. Med. 99 (1983) 22-26.
2. Steere, A. C., Green, J., Schoen, R. T., Taylor, E., Hutchinson, G. J., Rahn, D. W.: Successful parenteral therapy of established Lyme disease. N. Engl. J. Med. 312 (1985) 869-874.
3. Kristoferitsch, W., Baumhackl, U., Sluga, E., Stanek, G., Zeiler, K.: High dose penicillin therapy in meningopolyneuritis Garin-Bujadoux-Bannwarth. Clinical and cerebrospinal fluid data. Zbl. Bakt. Mikrobiol. Hyg. A 263 (1986) 357-364.
4. Barbour, A. G.: Isolation and cultivation of Lyme disease spirochetes. Yale J. Biol. Med. 57 (1984) 71-75.
5. Weber, K., Neubert, U-, Thurmayr, R.: Antibiotic therapy in early erythema migrans disease and related disorders. Zbl. Bakt. Mikrobiol. Hyg. A 263 (1986) 377-388.
6. Frautschi von Saanen, C.: Stellenwert der Penicillintherapie beim Erythema chronicum migrans in Hinblick auf Spätkomplikationen. Inaugural Dissertation an der Universität Bern, Schweiz 1988.
7. Hansen, K., Hovmark, A., Lebech, A. M., Olsson, K., Halkier-Sorensen, I., Olsson, I., Sorensen, L.: Roxithromycin in Lyme borreliosis. Acta. Derm. Venereol. 72 (1992) 297-300.
8. Preac-Mursic, V., Wilske, B., Schierz, G.: European Borrelia burgdorferi isolated from humans and ticks. Culture conditions and antibiotic susceptibility. Zbl. Bakt. Mikrobiol. Hyg. A 263 (1986) 112-118.
9. Baranton, G., Postic, D., Saint Girons, I., Boerlin, P., Piffaretti, J.-C., Assous, M., Grimiont, P. A. D.: Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme borreliosis. Int. J. Syst. Bacteriol. 42 (1992) 378-383.
10. Ericsson, H. M., Sherris, J. C.: Antibiotic sensitivity testing. Acta Path. Microbiol. Scand. Sect. B, Suppl. 217 (1971).
11. Pfister, H. W., Preac Mursic, V., Wilske, B., Schielk, E., Sörgel, F., Einhäupl, K. M.: Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J. Infect. Dis. 163 (1991) 311-318.